
ASK THE EXPERTS
EXPERTS DISCUSS HEREDITARY GASTROINTESTINAL (GI) CANCER
RISK, SCREENING, PREVENTION AND TREATMENT



"FORCE improves the lives of the millions of individuals and families facing hereditary cancers.

FORCE Programs



Support

Personalized Peer Support

Virtual Support Groups

Private Facebook Group and Message Boards

Helpline




Advocacy & Public Policy

State & Federal Advocacy Efforts

Advocacy Day

Patient Advocate Leader Training

Take Action Campaigns



Education

Information on Genes & Hereditary Cancers

XRAY – Behind the Cancer Headlines

Educational Brochures & Decision Guides

Ask the Experts Webinar Series



Research

Research Matching and Targeted Study Promotion

Researcher Training, Assistance and Collaborations

Research Advocate Training

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Presenting Sponsor



Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Empowerment Sponsors





FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Affinity Sponsors







FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Community Sponsors

FOUNDATION MEDICINE

Pfizer Oncology

EXACT SCIENCES

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Ask the Experts

1. **Expert interviews**
   This portion will be recorded.

2. **Breakout sessions**
   Group discussion and question and answers.

Proprietary and Confidential. All Rights Reserved.

Speakers



Michael Hall, MD, MS

GI Oncologist

Fox Chase Cancer Center



Bryson Katona, MD, PhD

Gastroenterologist


University of Pennsylvania

Proprietary and Confidential. All Rights Reserved.

Gastrointestinal System

Focus of this webinar

- Stomach
- Colorectal
- Pancreas



Section 1

GI Cancer Risk

Genes Associated with Colorectal Cancer Risk

Very Elevated Risk	APC, BMPR1A, MLH1, MSH3*, MSH2/EPCAM MUTYH*, NTHL1*,POLD1, POLE, SMAD4, STK11	*Applies to people with mutations in both copies of the gene.
Moderate to High Risk	MSH6, PMS2, STK11	
Somewhat Elevated Risk	APCI1307K, PTEN, MUTYH*, GREM1**, MBD4**, RNF43**, TP53**, AXIN2**	*Applies to people with a mutation in one copy of their MUTYH gene. **More research is needed to confirm a link for some of these genes.

Proprietary and Confidential. All Rights Reserved.


FORCE
Facing Hereditary Cancer EMPOWERED



Other Factors Associated with Colorectal Cancer Risk

- ↓ Fruits and vegetables
- ↓ High-fiber diet
- ↓ Exercise
- ↓ Aspirin
- ↓ Calcium

- ↑ Meat
- ↑ Processed foods
- ↑ Alcohol
- ↑ Obesity
- ↑ Smoking



Lynch Syndrome Genes

1. EPCAM
2. MLH1
3. MSH2
4. MSH6
5. PMS2

Proprietary and Confidential. All Rights Reserved.

Genes Associated with Stomach Cancer Risk

Stomach Cancer Risk Genes	Stomach Cancer Risk Associated with H. Pylori Infection
APC CDH1, CTNNA1 MLH1, MSH2/EPCAM, MSH6, PMS2 SMAD4, BMPR1A, STK11, TP53	ATM BRCA1 BRCA2

Proprietary and Confidential. All Rights Reserved.

FORCE
Facing Hereditary Cancer EMPOWERED



Other Factors Associated with Gastric Cancer Risk

- ↓ Fruits and vegetables
- ↓ Refrigeration of food
- ↓ Coffee
- ↓ Exercise

- ↑ High salt, processed and pickled foods
- ↑ Alcohol
- ↑ Smoking
- ↑ Obesity
- ↑ Infection: H. pylori

H. Pylori and Gastric Cancer Risk





Relevance: Medium-High

Most relevant for: People who are at increased risk for stomach cancer due to an inherited mutation.

Study: H. pylori bacteria infection and risk of stomach cancer in mutation carriers

The results of a study in Japan show that people with a bacterial infection called *H. pylori* and an inherited mutation in an *ATM, BRCA1, BRCA2* or *PALB2* gene have a high risk of stomach cancer. (Posted 1/19/24)

Este artículo está disponible en español.

READ MORE ›

bit.ly/force-xray-hpylori

Genes Associated with Pancreatic Cancer Risk

High Risk	CDKN2A, PRSS1, SPINK1, STK11
Increased Risk	ATM, BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PALB2, TP53
Pancreatic Neuroendocrine Tumors PNETs	CDKN1B, MEN1, NF1, TSC1/TSC2, VHL

Proprietary and Confidential. All Rights Reserved.

FORCE
Facing Hereditary Cancer EMPOWERED

Pancreatic Cancer and Oral Biome



JAMA Oncology

Home | Issues | Multimedia | For Authors

Home | JAMA Oncology | New Online

Original Investigation

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Yixuan Meng, PhD[1,2]; Feng Wu, PhD[1,2]; Soyoung Kwak, PhD[1,2] ; et al

Author Affiliations | Article Information

[1]Department of Population Health, NYU Grossman School of Medicine, New York, New York

[2]NYU Laura and Isaac Perlmutter Cancer Center, New York, New York

Cite | Permissions | Metrics

JAMA Oncol

Published Online: September 18, 2025

doi: 10.1001/jamaoncol.2025.3377


PLACEHOLDER FOR XRAY REVIEW

Section 2

GI Cancer Screening & Prevention

EUS (Esophageal Ultrasound)

Involves passing a tiny scope with an attached ultrasound probe down the esophagus to the stomach to better see the pancreas.



Contrast Enhanced MRCP

(Magnetic Resonance Cholangiopancreatography)

A special type of MRI imaging that looks closely at the pancreas, liver, gallbladder, bile duct and pancreatic duct to find abnormalities such as cancer.

Pancreatic Cancer Screening Guidelines

Screening involves an annual MRCP or EUS

Gene/s	Guidelines	Age to Begin Screening	Notes
PRSS1, SPINK1	Consider annual screening	Beginning 20 years after onset of pancreatitis symptoms or at age 40 (whichever is earlier)	People with these mutations who also have chronic pancreatitis
STK11	Consider annual screening	Beginning at age 30-35 or 10 years earlier than the earliest pancreatic cancer in the family	No family history needed
CDKN2A	Consider annual screening	Beginning at age 40 or 10 years earlier than the earliest pancreatic cancer in the family	No family history needed
ATM, BRCA2	Consider annual screening	Beginning at age 50 or 10 years earlier than the earliest pancreatic cancer in the family	No family history needed
BRCA1, MLH1, MSH2/EPCAM, MSH6, PALB2, TP53	Consider annual screening	Beginning at age 50 or 10 years earlier than the earliest pancreatic cancer in the family	For people with one or more 1st- or 2nd-degree relatives with pancreatic cancer

Proprietary and Confidential. All Rights Reserved.

FORCE
Facing Hereditary Cancer EMPOWERED

Section 2

GI Cancer Screening & Prevention

Resistant Starch and GI Cancer Risk





Relevance: Medium-High

Most relevant for: People with Lynch syndrome and people with a personal and/or family history that suggests Lynch syndrome

Study: Resistant starch may help prevent some cancers in people with Lynch syndrome


This study looked at whether a type of nutrient known as resistant starch could lower the risk of cancers in people with Lynch Syndrome. Researchers found that resistant starch can reduce the risk of non-colorectal cancers but not colorectal cancer. (Posted 10/17/22)

Este artículo está disponible en español.

READ MORE ›

bit.ly/force-xray-resistant-starch

FORCE Survey on Gastric Cancer Risk in People with Inherited Mutations



Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

bit.ly/force-stomach-cancer-survey

Colorectal Cancer Screening and Prevention Studies



Using the Drug eRapa to Prevent the Growth of Polyps in People with Familial Adenomatous Polyposis (SERENTA)

bit.ly/force-fap-erapa-study



Early Detection of Colorectal Cancer for People with Lynch Syndrome

bit.ly/force-lynch-screening-study

Colorectal Cancer Screening and Prevention Studies



My Best GI Eating Study

bit.ly/force-best-eating-study



Studying the Use of Naproxen and Aspirin for Cancer Prevention in People with Lynch Syndrome

bit.ly/force-naproxen-lynch-study

Pancreatic Cancer Screening Studies



Pancreatic Cancer Screening Study (CAPS5)

bit.ly/force-caps5

PRECEDE
The Pancreatic Cancer Early Detection Consortium

Pancreatic Cancer Early Detection for People at High Risk: PRECEDE

bit.ly/force-precede-study

Pancreatic Cancer Screening Studies



Blood Markers of Early Pancreas Cancer

bit.ly/markers-of-pancreatic-cancer



Screening Study for Pancreatic Cancer in People with Inherited Mutations

bit.ly/force-ucsf-panc-screening

Section 3

GI Cancer Treatment

Colorectal Cancers

ATOMIC Study

2025 ASCO ANNUAL MEETING

ATOMIC: Atezolizumab + FOLFOX Significantly Improves DFS, Reduces Recurrence Risk in Stage III dMMR Colon Cancer

June 1, 2025

ALASCCA Study

The NEW ENGLAND JOURNAL of MEDICINE

CURRENT ISSUE SPECIALTIES TOPICS

ORIGINAL ARTICLE

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer

Authors: Anna Martling, M.D., Ph.D. , Ida Hed Myrberg, M.Sc., Mef Nilbert, M.D., Ph.D., Henrik Grönberg, M.D., Ph.D., Fredrik Granath, Ph.D., Martin Eklund, Ph.D., Tom Öresland, M.D., Ph.D., +12 , for the ALASCCA Study Group* Author Info & Affiliations

Published September 17, 2025 | N Engl J Med 2025;393:1051-1064 | DOI: 10.1056/NEJMoa2504650

VOL. 393 NO. 11 | Copyright © 2025

RESET-C Study

Journal of Clinical Oncology®
An American Society of Clinical Oncology Journal

Meeting Abstract: 2025 ASCO Gastrointestinal Cancers Symposium

FREE ACCESS | Colorectal Cancer | January 27, 2025

Single-cycle neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: Final analysis of the RESET-C study.

Authors: Camilla Qvortrup, Tobias Freyberg Justesen, Line Schmidt Tarpgaard, Mustafa Bulut, Torben Hansen, Hans B. Rahr, Peter Clausager Petersen, ...

SHOW ALL ... , and Ismail Gögenur | AUTHORS INFO & AFFILIATIONS

Publication: Journal of Clinical Oncology • Volume 43, Number 4_suppl • https://doi.org/10.1200/JCO.2025.43.4_suppl.19

CHALLENGE Study

Movement Is Medicine: Structured Exercise Program May Lower Risk of Cancer Recurrence and Death for Some Colon Cancer Survivors

Jun 1, 2025

Section 3

GI Cancer Treatment

Gastric Cancers

Zolbetuximab

Journal of Clinical Oncology®
An American Society of Clinical Oncology Journal

CURRE

Meeting Abstract: 2025 ASCO Annual Meeting I

FREE ACCESS | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | May 28, 2025

Unlocking the potential of zolbetuximab in CLDN18.2-positive gastric cancer: A comprehensive systematic review of clinical efficacy and safety.

Authors: Owais Gul, Anam Ashfaque, Aiman Waheed, Sanan Rasheed, Bibi Maryam, Roshan Afshan, and Muhammad Hamza Gul | AUTHORS INFO & AFFILIATIONS

Publication: Journal of Clinical Oncology • Volume 43, Number 16_suppl • https://doi.org/10.1200/JCO.2025.43.16_suppl.e16069

Definition

HIBEC stands for Hyperthermic Intraperitoneal Chemotherapy.

At the end of surgery to remove tumors, the abdominal cavity is bathed in a heated, highly concentrated chemotherapy solution to eliminate any remaining cancer.

Proprietary and Confidential. All Rights Reserved.

Section 3

GI Cancer Treatment

Pancreatic Cancers

KRAS Vaccine Study

Brief Communication | Open access | Published: 11 August 2025

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Zev A. Wainberg ✉, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq ✉, Shubham Pant ✉ & Eileen M. O'Reilly ✉

Nature Medicine (2025) | Cite this article

Definition

CAR-T stands for Chimeric Antigen Receptor T-cell.

A type of immune therapy that uses a patient's own genetically modified T cells to fight cancer.

Proprietary and Confidential. All Rights Reserved.

TAPUR Study

Journal of Clinical Oncology®
An American Society of Clinical Oncology Journal

CURREN

Meeting Abstract: 2025 ASCO Gastrointestinal Cancers Symposium

FREE ACCESS | Pancreatic Cancer | January 27, 2025

Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with *BRCA1/2* mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Authors: Peter Joel Hosein, Michael Rothe, Elizabeth Garrett-Mayer, Ari David Baron, Timothy Lewis Cannon, Evan P. Pisick, Evthokia Hobbs, ... SHOW ALL

... , and Richard L. Schilsky | AUTHORS INFO & AFFILIATIONS

Publication: Journal of Clinical Oncology • Volume 43, Number 4_suppl • https://doi.org/10.1200/JCO.2025.43.4_suppl.715

Treatment Clinical Trials for Colorectal Cancer



The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer

bit.ly/force-tala-solid-tumors



Using ctDNA for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

bit.ly/force-ctdna-crc-study

Treatment Clinical Trials for Pancreatic Cancer



Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

bit.ly/force-apollo-study



Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients' Stem Cells


bit.ly/force-sharon-study

Clinical Trials for Advanced Cancers (Including GI)



Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

bit.ly/force-moma-341



Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

bit.ly/force-nivo-relatlimab-study

Clinical Trials for Advanced Cancers (Including GI)



Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

BRCA1 or BRCA2

bit.ly/force-xl-309-study



Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors

bit.ly/force-atr-study

Closing Thoughts

Thank You! Please Complete our Short Feedback Survey



bit.ly/ask-the-experts-gi-feedback

Proprietary and Confidential. All Rights Reserved.

Join Us for our Next Hereditary Cancer Update

December 4, 2025 at 2 pm

bit.ly/force-updates

Proprietary and Confidential. All Rights Reserved.



Connect with us

www.FacingOurRisk.org

866-288-RISK

Info@FacingOurRisk.Org

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.